Product details
Background：Omalizumabachieves its efficacy by targeting and neutralizing IgE (immunoglobulin E) .Ige plays an important role in allergic reactions, and Omalizumab reduces itsamount, thereby reducing the occurrence of allergic symptoms. IgE-relatedresearch has driven the development of IgE-targeted biologics, and omalizumab,as the first anti-IgE agent, has demonstrated clear efficacy inmoderate-to-severe asthma and chronic spontaneous urticaria, and has been usedin the treatment of asthma and chronic urticaria, it provides a new option forpatients who do not respond well to traditional treatments.
